News | March 18, 2021
Merck accelerates expansion plans for single-use products critical to manufacturing vaccines
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
The vaccine was 85 percent effective in preventing severe disease across all regions.
Nitazoxanide Tablets, 500 mg (RLD: Alinia) had estimated annual sales of USD 56 million in the U.S.
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
The collaboration of two strong partners, CELLINK and UPM, builds confidence in making these treatments into an industrial and clinical standard, applied in a wider setting instead of remaining only within few hospitals.
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
The company received approval for 2-Methyl-5Nitro-Imidazole (2-MNI) with a committed production capacity of 4,000 MT per annum.
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
